expanded access programme (EAP) – a scheme that allows people to access a drug before it has been approved (but when approval is expected).
EAPs are for people urgently need treatment as a life-saving option and who do o have the time to wait for the six months that it takes for approval to be finalised. EAPs are usually available for most HIV drugs after the main studies (phase 3) have been completed.
They were an important early result of community activism. They are also called ‘early access’ or ‘named-patient’ programmes.
Stevens-Johnson Syndrome – a type of severe rash that is luckily rare. This rash has been reported in 0.1–0.3% of people using NNRTIs. It can also occur with other drugs including antibiotics (including cotrimoxazole/Septrin). Any rash on an NNRTI should be shown to your doctor to decide whether treatment needs to be switched or can continue.
boosted-PI – a protease inhibitor taken with an additional dose of ritonavir. The ritonavir boost levels of the protease inhibitor by either increasing the initial drugs levels or reducing how quickly or reducing how quickly it is removed by your body. Ritonavir (itself a protease inhibitor) is currently the only drug used in this way. Other boosters are in development including cobicistat which has no direct anti-HIV activity.
PCR (polymerase chain reaction) – type of viral load test.
confirmatory test – a second test to double-check the results of a previous one. For example, if your viral load is usually undetectable and then becomes detectable, you need a second confirmatory test. This is to check that the detectable result was not a laboratory error on just a temporary blip.
